Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia HiDAC + Pembrolizumab in R/R AML

Overview of attention for article published in Blood Cancer Discovery, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#41 of 204)
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 5 news outlets

twitter: 19 X users

Citations

dimensions_citation: 45 Dimensions

Readers on

mendeley: 32 Mendeley

Summary News X Dimensions citations

So far, Dimensions has found 45 publications that cite this research output.

45

The most recent citing publications are shown below. View all 45 publications that cite this research output on Dimensions.

Precision Medicine Approaches in Acute Myeloid Leukemia with Adverse Genetics

Article in International Journal of Molecular Sciences (April 2024)

Single-Cell CD4 and CD8 T Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy

Article in Cancer Research Communications (March 2024)

Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia

Article in Journal of Clinical Medicine (February 2024)